Camurus was founded in 1991 by scientists in physical, biophysical and food chemistry with expertise in lipid phase structures. They recognized the drug-delivery potential of lyotropic liquid crystal (LC) structures such as the novel Cubosome® nanoparticle. The first drug product based on LC delivery systems to reach the market using the special properties of liquid crystal phase structures was Elyzol® Dental Gel. This was introduced on the market in 1992 by Dumex on a license from Camurus and is now sold by Colgate® Oral Pharmaceuticals. Camurus is a provider of drug-delivery systems for peptides, proteins, and insoluble small molecules. The company's mission is to provide the pharmaceutical and biotech industry with effective drug delivery solutions for drugs with bioavailability limitations.